Common Stock, $0.0001 par value per share
- Symbol
- KROS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Keros Therapeutics, Inc.
KROSNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On September 28, 2026, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing that the first patient was dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.…
Registered securities in this filing
Keros Therapeutics, Inc. · 8-K · Filed 2026-09-28
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On September 28, 2026, Keros Therapeutics, Inc. (the “Company”) issued a press release announcing that the first patient was dosed in its Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.